Innovations in the Diagnosis and Treatment of Chronic Kidney Disease

Chronic kidney disease (CKD) affects millions of patients and is often underrecognized until it is advanced, limiting opportunities to slow progression and reduce complications. This Grand Rounds will examine current approaches to CKD diagnosis, risk stratification, and referral, with an emphasis on the clinical importance of albuminuria in guiding treatment decisions. The session will review evolving evidence for CKD therapies in patients with and without diabetes and will highlight strategies to personalize care, improve early recognition, and reduce kidney and cardiovascular risk.

Speaker:
Michael Shlipak, MD, MPH, is a professor of medicine in the Division of General Internal Medicine at the San Francisco VA Health Care System (SFVAHCS), the scientific director of the UCSF Kidney Health Research Collaborative, and the associate chief of medicine for research development at SFVAHCS. His research focuses on the detection and determinants of kidney disease and its association with cardiovascular outcomes. Shlipak is widely recognized for pioneering the use of cystatin C as a marker of kidney function and for his contributions to national and international guidelines for CKD diagnosis and treatment.

How to Attend: 
In Person: 
S-214, Medical Sciences Building (513 Parnassus Avenue) 
Lunch will be provided 

Zoom option: 
https://ucsf.zoom.us/j/97633865272?pwd=sHvIef57IXKYFnBm2lnvQtxUMeRVEn.1  
Webinar ID: 976 3386 5272 
Passcode: 609641 

Or join by phone (for higher quality, dial a number based on your current location): 
+1 669 900 6833 US (San Jose) 
+1 213 338 8477 US (Los Angeles) 
+1 669 219 2599 US (San Jose) 
+52 554 161 4288 (Mexico) 

International numbers available: https://ucsf.zoom.us/u/ac4WisOf7E  

New procedures for claiming CME credit:  
Please review this informational guide on the updated ways to claim CME credit starting in academic year 25-26.